Biogen Inc. reported second quarter 2026 financial results with total revenue of $2.7 billion, a 3% year-over-year increase. GAAP diluted EPS was $0.66 and Non-GAAP diluted EPS was $3.60. The company updated its full year 2026 Non-GAAP diluted EPS guidance to $12.00–$13.00, reflecting approximately $0.85 of dilution from the Apellis acquisition completed in May 2026. Biogen expects transaction run rate synergies of at least $250 million by exiting 2027 and remains on track for accretion in 2027. The company also announced Phase 2 proof-of-concept data for BIIB091 in multiple sclerosis and exercised an option to license BIIB147 from Ionis for a $15 million fee. Biogen Inc. is a biotechnology company that develops and commercializes treatments for neurological, neurodegenerative, and rare diseases.

Biogen Inc. expects to incur approximately $164 million in pre-tax acquired in-process research and development, upfront and milestone expenses for the second quarter of 2026, impacting net income per diluted share by approximately $0.95. The company also anticipates an estimated charge for the third quarter of 2026 ranging from $290 million to $320 million, which is expected to impact net income per diluted share by $1.75 to $1.95. Biogen is a biotechnology company that develops and manufactures products for neurological and related diseases.

Biogen Inc. filed this amendment to its May 14, 2026, Form 8-K to clarify that the acquisition of Apellis Pharmaceuticals, Inc. does not constitute a "significant" acquisition under Regulation S-X. Consequently, the company determined that it is not required to file financial statements of the acquired business or pro forma financial information. All other disclosures from the original report remain unchanged. Biogen is a biotechnology company focused on neurological and immunology therapies.

Biogen has completed its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion, funded in part by a new $2 billion term loan facility. The transaction includes contingent value rights (CVRs) that could pay up to $4.00 per share based on future SYFOVRE sales milestones. This acquisition expands Biogen's product portfolio but increases its leverage and introduces performance-linked contingent liabilities.

Biogen Inc. announced its financial results for the first quarter ended March 31, 2026, in a press release issued on April 29, 2026. This filing is material to investors as it provides the official update on the company's quarterly operational performance and financial condition.